<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053819</url>
  </required_header>
  <id_info>
    <org_study_id>F070629011</org_study_id>
    <nct_id>NCT01053819</nct_id>
  </id_info>
  <brief_title>Can We Miss Pigmented Lesions in Psoriasis Patients?</brief_title>
  <official_title>Can We Miss Pigmented Lesions in Psoriasis Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely&#xD;
      heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However,&#xD;
      successful systemic treatment and subsequent clearing of psoriatic plaques may allow&#xD;
      clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early&#xD;
      identification and treatment of suspicious lesions such as nonmelanoma skin cancer and&#xD;
      malignant melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No further description is desired.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</measure>
    <time_frame>Patients will complete study within 6 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria</measure>
    <time_frame>Patients will complete the study within 6 months</time_frame>
    <description>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Psoriasis</condition>
  <condition>Melanoma</condition>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of moderate to severe plaque psoriasis identified by a BSA greater than or&#xD;
             equal to 10% and a Psoriasis Area and Severity Index score greater than or equal to 12&#xD;
&#xD;
          2. Age 19 years or above&#xD;
&#xD;
          3. Fitzpatrick skin type I, II or III&#xD;
&#xD;
          4. Candidate for systemic treatment in the opinion of the investigator&#xD;
&#xD;
          5. Willingness to undergo treatment with Enbrel as outlined above&#xD;
&#xD;
          6. Negative pregnancy test (urine or serum Î²-Human Chorionic Gonadotrophin ) before the&#xD;
             first dose of study drug in all women (except those surgically sterile, or at least 5&#xD;
             years postmenopausal).&#xD;
&#xD;
          7. Negative Tuberculosis skin test at entry into the study or a negative screening x-ray&#xD;
             in inconclusive Purified Protein Derivative reading (borderline, reactive but&#xD;
             non-diagnostic) or in prior bacille Calmette-Guerin inoculated subjects.&#xD;
&#xD;
          8. Sexually active subjects of childbearing potential must agree to use medically&#xD;
             acceptable form of contraception during screening and throughout the study&#xD;
&#xD;
          9. Subject or designee must have the ability to self-inject study medication or have a&#xD;
             care giver at home who can administer subcutaneous injections&#xD;
&#xD;
         10. Must be able and willing to give written informed consent and comply with the&#xD;
             requirements of the study protocol and must authorize release and use of protected&#xD;
             health information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum creatinine &gt; 3.0 mg/dL (265 micromoles/L)&#xD;
&#xD;
          2. Serum potassium &lt; 3.5 mmol/L or &gt; 5.5 mmol/L&#xD;
&#xD;
          3. Serum alanine aminotransferase or Aspartate transaminase &gt; 3 times the upper limit of&#xD;
             normal for the Lab&#xD;
&#xD;
          4. Platelet count &lt; 100,000/mm3&#xD;
&#xD;
          5. White blood cell count &lt; 3,000 cells/mm3&#xD;
&#xD;
          6. Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower&#xD;
             limits of normal for the Lab&#xD;
&#xD;
          7. Systemic therapy use (e.g. phototherapy, methotrexate, cyclosporine, oral steroids,&#xD;
             systemic biologics) within the previous 4 weeks&#xD;
&#xD;
          8. Topical therapy use (e.g. topical steroids, vitamin D derivatives) within the previous&#xD;
             2 weeks&#xD;
&#xD;
          9. Subject is currently enrolled in another investigational device or drug trial(s), or&#xD;
             subject has received other investigational agent(s) within 28 days of baseline visit.&#xD;
&#xD;
         10. Subjects who have known hypersensitivity to Enbrel or any of its components or who is&#xD;
             known to have antibodies to etanercept&#xD;
&#xD;
         11. Prior or concurrent cyclophosphamide therapy&#xD;
&#xD;
         12. Concurrent sulfasalazine therapy&#xD;
&#xD;
         13. Known Human immunodeficiency virus-positive status or known history of any other&#xD;
             immunosuppressing disease&#xD;
&#xD;
         14. Active severe infections within 4 weeks before screening visit, or between the&#xD;
             screening and baseline visits&#xD;
&#xD;
         15. Untreated Lyme disease&#xD;
&#xD;
         16. Severe comorbidities (diabetes mellitus requiring insulin, CHF of any severity, MI,&#xD;
             CVA or TIA within 3 months of screening visit, unstable angina pectoris, uncontrolled&#xD;
             hypertension (sitting systolic BP &lt;80 mm Hg or &gt; 160 or diastolic BP &gt; 100 mm Hg),&#xD;
             oxygen-dependent severe pulmonary disease, history of cancer within 5 years [other&#xD;
             than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer])&#xD;
&#xD;
         17. History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of&#xD;
             multiple sclerosis, transverse myelitis, optic neuritis or epilepsy&#xD;
&#xD;
         18. History of recent alcohol or substance abuse (&lt; 1 year)&#xD;
&#xD;
         19. Pregnant or lactating females&#xD;
&#xD;
         20. Use of a live vaccine 90 days prior to, or during this study&#xD;
&#xD;
         21. Any condition judged by the patient's physician to cause this clinical trial to be&#xD;
             detrimental to the patient&#xD;
&#xD;
         22. History of non-compliance with other therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boni E Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2012</results_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Boni Elewski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>melanoma</keyword>
  <keyword>non-melanoma skin cancer</keyword>
  <keyword>etanercept</keyword>
  <keyword>Enbrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Patients will receive six months of treatment with Enbrel 50mg SC given twice a week for the first three months and 50 mg once a week thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>open label treatment per FDA approval for 24 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</title>
        <time_frame>Patients will complete study within 6 months.</time_frame>
        <population>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>open label treatment per FDA approval for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.</title>
          <population>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria</title>
        <description>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</description>
        <time_frame>Patients will complete the study within 6 months</time_frame>
        <population>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients will receive six months of treatment with Enbrel 50mg SC given twice a week for the first three months and 50 mg once a week thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria</title>
          <description>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</description>
          <population>The data for this Outcome was not collected and due to the length of time, the records have been destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>open label treatment per FDA approval for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boni Elewski, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-502-9960</phone>
      <email>beelewski@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

